DRAP says that reports of price increases for important drugs are not true.

The Drug Regulatory Authority of Pakistan (DRAP) has called claims of a recent rise in the prices of important medicines “baseless.”

A DRAP spokesperson said that the pricing of insulin and other life-saving drugs have not gone up. Pharmaceutical corporations can’t raise the prices of important drugs on their own.

The representative went on to say that all required steps are being made to make sure that medicines are always available. As a regulator, DRAP has sent two important notices to drug companies.

Companies have been told to get their raw materials from more than one place. About 85% of the medicines used in Pakistan are made there.

Even though things are going wrong and routes may be blocked, the supply of medicines is still steady. Representatives from the industry have also said that there is no fear of the country running out of medications.

Most businesses now have enough raw materials and finished goods on hand to meet demand for the next four to six months.

The Competition Commission of Pakistan (CCP) and the Drug Regulatory Authority of Pakistan (DRAP) signed a memorandum of understanding earlier to work together better.

The MoU says that both groups would share information and statistics to help the government keep an eye on the pharmaceutical sector better.

Details say that the two bodies agreed to work together on policy studies, sharing data, and strengthening their own skills.

A whole framework would be established to make sure that drug pricing and availability are tracked well across the country.